CombiMatrix said that it had record prenatal microarray volume of 1,126 tests in the fourth quarter.
NanoString CEO Brad Gray said on a conference call that oncology was once a primary driver of new instrument placements.
The firm said that it placed 38 XT-8 analyzers in Q4, bringing the total installed base of the instrument to 540 as of the end of 2014.
The firm is also positioning MassArray as a complementary technology to NGS, and hopes to tap into the LDT and liquid biopsy arenas.
The molecular diagnostics firm offered more than 3.2 million shares of its stock at $2.80 per share as part of the offering.
A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.
National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.
In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.
The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.